2019

• Fremanezumab (Ajovy®)
• Olaparib (Lynparza®) for breast cancer
• Opium Tincture (Dropizol®
• Pembrolizumab (Keytruda ®) 1L squamous NSCLC with chemotherapy
• Cerliponase alfa (Brineura®)
• Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L
• Dabrafenib plus Trametinib (Tafinlar® plus Mekinist®)
• Carfilzomib (Kyprolis®) in combination with dexamethasone (CAR+DEX).
• Daratumumab (Darzalex®) combination therapy
• Liraglutide (Victoza®)
• Apalutamide (Erleada®) for nmCRPC
• Patiromer (Veltassa®)
• Enzalutamide (Xtandi®) for nmCRPC
• Pertuzumab (Perjeta®) for Adjuvant HER2 positive breast cancer
• Blinatumomab (Blincyto®) (paediatric ALL)
• Budesonide orodispersible tablet (Jorveza®)
• Pentosan Polysulfate Sodium [PPS] (Elmiron®)
• Tivozanib (Fotivda®)
• Encorafenib (Braftovi®), binimetinib (Mektovi®)
• Diclofenac (Itami®)
• Doravirine (Pifeltro®)
• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo®)
• Alectinib (Alecensa®)
• Patisaran (Onpattro®)

2018

• Burosumab (Crysvita®)
• Cariprazine (Reagila®)
• Ozenoxacin (Dubine®)
• Ropivacaine Readyfusor®
• Brigatinib (Alunbrig®)
• Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)
• Pembrolizumab (Keytruda®) for Adjuvant melanoma
• Lesinurad (Zurampic®)
• Ixekizumab (Taltz®) for psoriatic arthritis
• Lutetium (177Lu) Oxodotreotide (Lutathera®)
• Abiraterone acetate (Zytiga®) for mHSPC
• Liposomal daunorubicin and cytarabine (CPX-351)(Vyxeos®)
• Dinutuximab beta (Qarziba®)
• Tisagenlecleucel (Kymriah®) for ALL
• Axicabtagene Ciloleucel (Yescarta®)
• Tisagenlecleucel (Kymriah®) for DLBCL
• Venetoclax (Venclyxto®) in combination with rituximab
• Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events
• Avelumab (Bavencio®)
• Ocrelizumab (Ocrevus®) for PPMS
• Olaparib (Lynparza®) for platinum sensitive relapsed ovarian cancer
• Atezolizumab (Tecentriq®)
• Tofacitinib (Xeljanz®) for Ulcerative Colitis
• Inotuzumab ozogamicin (Besponsa®)
• Nivolumab (Opdivo®) for urothelial carcinoma
• Tolvaptan (Jinarc®)
• Midostaurin (Rydapt®) for ASM
• Midostaurin (Rydapt®) for AML
• Idebenone (Raxone®)
• Ocrelizumab (Ocrevus®) for RMS
• Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy
• Lenvatinib (Lenvima®) for HCC
• Erenumab (Aimovig®)
• Ribociclib (Kisqali®)
• Osimertinib (Tagrisso®) for the first-line treatment of metastatic NSCLC
• Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of adults with melanoma
• Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 1L
• Urea (GlucoRx Allpresan®)
• Cladribine (Mavenclad®)
• Gemtuzumab ozogamicin (Mylotarg®)
• Darvadstrocel (Alofisel®)
• Dolutegravir/Rilpivirine (Juluca®)
• Cabozantinib (Cabometyx®)
• Niraparib (Zejula®)
• Venetoclax (Venclyxto®)
• Glycerol Phenylbutyrate (Ravicti®)
• Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)
• Sebelipase alfa (Kanuma®)
• Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®)
• Pembrolizumab (Keytruda®) for NSCLC (second line)
• Selexipag (Uptravi®)
• Ertugliflozin (Steglatro®)
• Recombinant Human Parathyroid Hormone (Natpar®)
• Evolocumab (Repatha®)
• Tafamadis meglumine (Vyndaqel®)
• Letermovir (Prevymis®)
• Naltrexone / bupropion (Mysimba®)
• Osimertinib (Tagrisso®)
• Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma
• Eliglustat (Cerdelga®)
• Blinatumomab (Blincyto®)
• Semaglutide (Ozempic®)
• Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®)
• Teduglutide (Revestive®)
• Brentuximab vedotin (Adcetris®) for CD30+ cutaneous T-cell lymphoma (CTCL)
• Benralizumab (Fasenra®)
• Dimethyl fumarate (Skilarence®)
• Guselkumab (Tremfya®)
• Modified Release Hydrocortisone (Plenadren®)

2017

• Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma
• Emtricitabine/tenofovir disoproxil (TEVA®)
• Nusinersin (Spinraza®)
• Ixazomib (Ninlaro®)
• Tramadol hydrochloride/dexketoprofen (Skudexa®)
• Hyaluronic acid and co enzyme Q10 (VisuXL®)
• Dupilumab (Dupixent®)
• Rivaroxaban (Xarelto®) low dose for prevention of recurrent venous thromboembolism
• Rivaroxaban (Xarelto®) for Atrial Fibrillation patients undergoing PCI
• Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)
• Cysteamine bitartrate delayed-release (Procysbi®)
• Lacosamide (Vimpat ®)
• Obeticholic acid (Ocaliva®)
• Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (Symtuza®)
• Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic
• Pembrolizumab (Keytruda®) for NSCLC (first line)
• Sarilumab (Kevzara®)
• Sapropterin (Kuvan®)
• Etelcalcetide (Parsabiv®)
• Glecaprevir/Pibrentasvir (Maviret®)
• Brodalumab (Kyntheum®)
• Follitropin delta (Rekovelle®)
• Stiripentol (Diacomit®)
• Palbociclib (Ibrance®)
• Emtricitabine / tenofovir disoproxil fumarate (Truvada®)
• Liposomal irinotecan (Onivyde®)
• Baricitinib (Olumiant®)
• Pitolisant hydrochloride (Wakix®)
• Insulin aspart (Fiasp®)
• Bezlotoxumab (Zinplava®)
• Ceftazidime-avibactam (CEF-AVI)(Zavicefta®)
• Rolapitant (Varuby®)
• Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)
• Alirocumab (Praluent®)
• Migalastat (Galafold®)
• Lenvatinib (Kisplyx®)
• Nivolumab (Opdivo®) for head and neck cancer
• Dalbavancin (Xydalba®)
• Tofacitinib (Xeljanz®)
• Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)
• Crizotinib (Xalkori®) for ROS1 NSCLC
• Crizotinib (Xalkori®) for first line ALK+ NSCLC
• Glycopyrronium bromide (Sialanar®)
• Nivolumab (Opdivo®) for advanced renal cell carcinoma
• Levonorgestrel intrauterine delivery system LNG IUS 12 (Kyleena®)
• Trametinib (Mekinist®)
• Daratumumab (Darzalex®)
• Mepolizumab (Nucala®)
• Reslizumab (Cinqaero®)
• Amsacrine (Amsidine®)
• Epoprostenol (Veletri®)
• Obinutuzumab (Gazyvaro®) for Follicular Lymphoma
• Nivolumab (Opdivo®) for classical Hodgkin Lymphoma
• Ustekinumab (Stelara®) for Crohn’s Disease
• Cobimetinib (Cotellic®)
• Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.

2016

• Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride (Fydrane®)
• Human alpha1-proteinase inhibitor (Respreeza®)
• Elosulfase alfa (Vimizim®)
• Daclizumab (Zinbryta®)
• Vortioxetine (Brintellix®)
• Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)
• Carfilzomib (Kyprolis®) in combination with lenalidomide and dexamethasone (CAR+LEN+DEX)
• Insulin degludec/liraglutide (IDegLira) (Xultophy®)
• Elbasvir/Grazoprevir (Zepatier®)
• Ivacaftor (Kalydeco®) for patients with CF 2 years +
• Nivolumab (Opdivo®) for non-squamous NSCLC
• Ferric maltol (Feraccru®)
• Aceclofenac (Vitafen®)
• Ibrutinib (Imbruvica®) for previously untreated CLL
• Sofosbuvir/Velpatasvir (Epclusa®)
• Ruxolitinib (Jakavi®) for Polycythaemia Vera
• Loxapine inhalation powder (Adasuve®)
• Ixekizumab (Taltz®)
• Ramucirumab (Cyramza®)
• Trifluridine/tipiracil (Lonsurf®)
• Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) (Odefsey®)
• Sacubitril/valsartan (Entresto®)
• Safinamide methansulfonate (Xadago®)
• Calcipotriol and betamethasone dipropionate cutaneous foam (Enstilar ®)
• Lumacaftor/ivacaftor (Orkambi®)
• Ulipristal acetate (Esmya ®) intermittent treatment
• Etanercept (Benepali®)
• Pertuzumab (Perjeta®) in neoadjuvant HER2 positive breast cancer
• Isavuconazole (Cresemba®) for the treatment of invasive aspergillosis.
• Isavuconazole (Cresemba®) for the treatment of mucormycosis
• Ticagrelor (Brilique®)
• Apremilast (Otezla®) for psoriatic arthritis.
• Ataluren (Translarna®)
• Emtricitabine/tenofovir alafenamide (Descovy®)
• Ceftolozane/tazobactam (Zerbaxa®)
• Nintedanib (Vargatef®)
• Brivaracetam (Briviact®)
• Sufentanil (Zalviso®)
• Nivolumab (Opdivo®) for Melanoma
• Talimogene Laherparepvec (Imlygic®)
• Nivolumab (Opdivo®) for NSCLC
• Levofloxacin (Quinsair®)
• Fluocinolone acetonide (Iluvien®)
• Eltrombopag (Revolade®) for Severe Aplastic Anaemia (SAA)
• Nintedanib (Ofev®)
• Idelalisib (Zydelig®)
• Paritaprevir boosted with ritonavir and ombitasvir (Vierkirax®) with or without dasabuvir (Exviera®)
• Panobinostat (Farydak®)
• Pembrolizumab (Keytruda®) for the first line treatment of unresectable or advanced metastatic melanoma in adults.
• Pembrolizumab (Keytruda®) for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.
• Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.
• Ciclosporin 1mg/ml eye drops (Ikervis®)
• Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide (Genvoya®)
• Ponatinib (Iclusig®)

2015

• Methoxyflurane (Penthrox®)
• Guanfacine hydrochloride (Intuniv®)
• Idarucizumab (Praxbind®)
• Olaparib (Lynparza®)
• Secukinumab (Cosentyx®) for Psoriatic Arthritis
• Secukinumab (Cosentyx®) for Ankylosing Spondylitis
• Lenalidomide (Revlimid®)
• Iron (III) isomaltoside 1000 (Monover®)
• Iron (III) isomaltoside 1000 (Diafer®)
• Ledipasvir/sofosbuvir (Harvoni®)
• Vedolizumab (Entyvio®) in Ulcerative Colitis
• Vedolizumab (Entyvio®) in Crohn’s Disease
• Netupitant/palonosetron (Akynzeo®)
• Insulin Glargine (Abasaglar®)
• Ibrutinib (Imbruvica®) for MCL
• Ibrutinib (Imbruvica®) for CLL
• Lidocaine 5% plasters (Versatis®)
• Secukinumab (Cosentyx®)
• Tedizolid phosphate (Sivextro®)
• Ceritinib (Zykadia®)
• Camellia sinensis, folium (green tea leaf) (Catephen 10%®)
• Lenvatinib (Lenvima®)
• Edoxaban (Lixiana®)
• Insulin Glargine U300 (Toujeo®)
• Omalizumab (Xolair®) for the treatment of severe allergic asthma
• Enzalutamide (Xtandi®) pre chemotherapy
• Daclatasvir (Daklinza®)
• St Johns Wort (Pacifa®)
• Romiplostim (Nplate®)
• Insulin Degludec (Tresiba®)
• Dulaglutide (Trulicity®)
• Naloxegel (Moventig®)
• Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia
• Pixantrone (Pixuvri®)
• Simeprevir (Olysio®) in combination with Sofosbuvir
• Pomalidomide (Imnovid®)
• Bedaquiline (Sirturo®)
• Aclidinium bromide / formoterol fumarate dihydrate (Brimica® Genuair®)
• Dimethyl fumarate (Tecfidera®)
• Telavancin (Vibativ®)
• Darunavir & cobicistat (Rezolsta®)

2014

• Pegylated Interferon beta-1a (Plegridy ®)
• Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)
• Pregabalin (Lyrica®) for the treatment of Generalised Anxiety Disorder
• Radium-223 (Xofigo®)
• Sofosbuvir (Solvaldi®)
• Polynuclear iron(III)-oxyhydroxide (pn-FeOOH) (Velphoro®)
• Regorafenib (Stivarga®) for GIST
• Rituximab (MabThera®)
• Lomitapide (Lojuxta®)
• Mannitol Dry Powder (Bronchitol®)
• Nab-paclitaxel (Abraxane®)
• Canagliflozin (Invokana®)
• Insulin aspart (NovoRapid® FlexTouch ®)
• Apixaban (Eliquis®) for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
• Cabozantinib (Cometriq®)
• Aripiprazole (Abilify Maintena®)
• Lixisenatide (Lyxumia®)
• Tocilizumab SC (RoActemra®)
• Defibrotide (Defitelio®)
• Simeprevir (Olysio®)
• Umeclidinium/vilanterol (Anoro®)
• Bosentan (Tracleer®)
• Ambrisentan (Volibris®)
• Alemtuzumab (Lemtrada®)
• Trastuzumab emtansine (Kadcyla®)
• Dabrafenib (Tafinlar®)
• Regorafenib (Stivarga®) for mCRC
• Buprenorphine/naloxone (Suboxone®)
• Teriflunomide (Aubagio®)
• Omalizumab (Xolair®)
• Dabigatran Etexilate (Pradaxa®) for the treatment of DVT and PE
• Empagliflozin (Jardiance®)
• Tadalafil (Adcirca®)
• Sildenafil (Revatio®)
• Riociguat (Adempas®)
• Brimonidine 3.3 mg/g gel (Mirvaso®)
• Clindamycin 1% with tretinoin 0.025% (Treclinac®)
• Oladaterol (Striverdi®, Respimat®)
• Avanafil (Spedra®)
• Brentuximab vedotin (Adcetris®)
• Enzalutamide (Xtandi®) on or after chemotherapy
• Nalmefene (Selincro®)
• Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml (Hyaneb®)
• Dolutegravir (Tivicay®)
• Abiraterone acetate (Zytiga®) for mCRPC post ADT
• Incobotulinum Toxin Type A (Xeomin®)
• Meningitis B Vaccine – February 2014
• Eltrombopag (Revolade®) for Thrombocytopenia in HCV
• Aflibercept (Zaltrap®)
• Macitentan (Opsumit®)
• Liquid Paraffin Ointment (VitA-POS Opthalmic®)
• Sodium Hyaluronate (Hyloforte® 0.2%)
• Sodium Hyaluronate (Hylotear® 0.1%)
• Vismodegib (Erivedge®)

2013

• Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®)
• Dapagliflozin (Forxiga®)
• Fluticasone furoate/vilanterol (Relvar™ Ellipta™)
• Abatacept (Orencia®)
• Alogliptin (Vipidia®)
• Golimumab (Simponi®) for UC
• Pregabalin (Lyrica®) for the treatment of neuropathic pain
• Ulipristal acetate (Esmya®) single course treatment
• Afatinib (Giotrif®)
• Eculizumab (Soliris®)
• Bosutinib (Bosulif®)
• Lipegfilgrastim (Lonquex®)
• Infliximab (Inflectra®)
• Imiquimod 3.75% (Zyclara®)
• Pertuzumab (Perjeta®)
• Crizotinib (Xalkori®)
• Rifaximin (Targaxan®)
• Sodium phenylbutyrate (Pheburane®)
• Icatibant (Firazyr®)
• Perampanel (Fycompa®)
• Ruxolitinib (Jakavi®)
• Ocriplasmin (Jetrea®)
• Linaclotide (Constella®)
• Colistimethate sodium (Colobreathe®)
• Vandetanib (Caprelsa®)
• Apixaban (Eliquis®) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
• Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumarate)(Stribild®)
• Omega-3-acid ethyl esters (Omacor®)
• Levonorgestrel intrauterine system LNG-IUS (Jaydess®)
• Pirfenidone (Esbriet®)
• Lisdexamfetamine dimesylate (Tyvense®)
• Azelastine hydrochloride and fluticasone propionate (nasal spray) (Dymista®)
• Fidaxomicin (Dificlir®)
• Ivacaftor (Kalydeco®)
• Mirabegron (Betmiga®)

2012

• Aflibercept (Eylea®)
• Decitabine (Dacogen®)
• Bendamustine (Levact®)
• Eribulin (Halaven®)
• Ingenol mebutate gel (Picato®)
• Axitinib (Inlyta®)
• C1inhibitor (human) (Cinryze®)
• Aclidinium bromide (Eklira Genuair®)
• Everolimus (Afinitor®)
• Ceftaroline (Zinforo®)
• Vemurafenib (Zelboraf®)
• Fampridine (Fampyra®)
• Ferumoxytol (Rienso®)
• Glycopyrronium bromide (Seebri Breezhaler®)
• Capsaicin 8%w/w patch (Qutenza®)
• Apixaban (Eliquis®) for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery
• Rivaroxaban (Xarelto®) for the Prevention of Stroke in Atrial Fibrillation
• Piperaquine tetraphosphate/dihidroartemisinin (Eurartesim®)
• Abiraterone Acetate (Zytiga®) for mCRPC
• Aspirin 81mg/Esomeprazole 20mg (Axanum®)
• Pasireotide (Signifor®)
• Tegafur/Gimeracil/Oteracil (Teysuno®)
• Dexamethasone Intravitreal Implant (Ozurdex®)
• Cabazitaxel (Jevtana®)
• Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis
• Belatacept (Nulojix®)
• Telaprevir (Incivo®)
• Boceprevir (Victrelis®)
• Azilsartan (Edarbi®)
• Rilpivirine (Edurant®)
• Nomegestrol acetate/estradiol (Zoely®)

2011

• Amifampridine (Firdapse®)
• Denosumab (Xgeva®)
• Lotemax 0.5% eye drops suspension (Loteprednol)
• Regadenoson (Rapiscan®)
• Everolimus (Votubia®)
• Grass pollen allergen extract (Oralair®)
• Ticagrelor (Brilique®)
• Oncotype DX®
• Fingolimod (Gilenya®)
• Asenapine (Sycrest®)
• Catumaxomab (Removab®)
• Dexmedetomidine (Dexdor®)
• Hydroxycarbamide (Siklos®)
• Ipilimumab (Yervoy®)
• Linagliptin (Trajenta®)
• Belimumab (Benlysta®)
• Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation
• Lornoxicam (Xefo®)
• Nepafenac (Nevanac®)
• Velaglucerase Alfa (VPRIV®)
• Collagenase Clostridium Histolyticum (Xiapex®)
• Exenatide (Bydureon®)
• Adalimumab (Humira®)
• Vernakalant (Brinavess®)
• Tapentadol (Palexia®)
• Paliperidone palmitate (Xeplion®)
• Tafluprost (Saflutan®)
• Retigabine (Trobalt®)
• Prucalopride (Resolor®)
• Bilastine (Drynol®)
• Iron isomaltoside 1000 (MonoVer®)
• Bazedoxifene (Conbriza®)

2010

• Pitavastatin (Livazo®)
• Tobramycin (TOBI Podhaler®)
• Gefitinib (Iressa®)
• Eltrombopag (Revolade®) for ITP
• Roflumilast (Daxas®)
• Corifollitropin alfa (Elonva®)
• Nilotinib (Tasigna®) newly diagnosed CML
• Dienogest (Visanne®)
• Certolizumab pegol (Cimzia®)
• Denosumab (Prolia®)
• Mifamurtide (Mepact®)
• Oxycodone/naloxone (Targin®)
• Ofatumumab (Arzerra®) (Refractory CLL)
• Golimumab (Simponi®)
• Colesevelam (Cholestagel®)
• Prasugrel (Efient®)
• Rotavirus Vaccine
• Indacaterol (Onbrez®)
• Dronedarone (Multaq®)

2009

• Agomelatine (Valdoxan®)
• Ustekinumab (Stelara®)
• Adenuric (Febuxostat®)
• Ranolazine (Ranexa®)
• Degarelix (Firmagon®)
• Eslicarbazepine (Zebinix®)
• Glucosamine sulfate (Dona®)
• Colorectal Cancer Screening programme

2008

• Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement
• Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement
• Melatonin (Circadin®)
• Human Papillomavirus Vaccine
• Nilotinib (Tasigna®) CML resistant/intolerant to imatinib
• Lapatinib (Tyverb®)

2007

• Sublingual Immunotherapy (Grazax®)
• Natalizumab (Tysabri®)
• Universal Infant Hepatitis B Vaccination programme
• Pneumococcal conjugate vaccine

2006

• Sunitinib (Sutent®)
• Rimonabant (Acomplia®)
• Inhaled insulin (Exubera®)